Study Meets Primary Endpoint of LDL Cholesterol Reduction First Phase 3 Data of a PCSK9 Inhibitor in Patients With Homozygous Familial Hypercholesterolemia – A Rare …
Study Meets Primary Endpoint of LDL Cholesterol Reduction First Phase 3 Data of a PCSK9 Inhibitor in Patients With Homozygous Familial Hypercholesterolemia – A Rare …